Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion

Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is defined as cardiotoxicity of a drug that manifests in the diseased (e.g., ischemic/reperfused), but not in the h...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cells
Autores principales: Brenner, Gábor B., Makkos, András, Nagy, Csilla Terézia, Onódi, Zsófia, Sayour, Nabil V., Gergely, Tamás G., Kiss, Bernadett, Görbe, Anikó, Sághy, Éva, Zádori, Zoltán S., Lázár, Bernadette, Baranyai, Tamás, Varga, Richárd S., Husti, Zoltán, Varró, András, Tóthfalusi, László, Schulz, Rainer, Baczkó, István, Giricz, Zoltán, Ferdinandy, Péter
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7140447/
https://ncbi.nlm.nih.gov/pubmed/32111102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9030551
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares